M&A Deal Summary |
|
|---|---|
| Date | 2017-10-30 |
| Target | Aviragen Therapeutics |
| Sector | Life Science |
| Buyer(s) | Vaxart |
| Deal Type | Merger |
| Advisor(s) | Stifel (Financial) Dechert (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 105 |
| Revenue | 29M USD (2024) |
Vaxart is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick injury. Its development programs are oral tablet vaccines designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart is based in South San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Merger M&A Deals | 1 of 1 |
| State: Georgia M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2017 M&A | 1 of 1 |
